Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 5/20 | 0.44 |
| ▸ | GABRD | O14764 | 5/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.44 |
| ▸ | GABRE | P78334 | 5/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16649308 | 0.83 | HSP90AA1 (0.38) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL8625804 | 0.81 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1540141 | 0.79 | HPGD (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14637332 | 0.79 | KEAP1 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL152156 | 0.78 | HPGD (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15530016 | 0.78 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10995891 | 0.77 | TSHR (0.46) | KDM4EALDH1A1MAPTHSP90AA1HPGD | |
| SCHEMBL11240852 | 0.77 | MEN1 (0.46) | KDM4EKMT2AMEN1ALDH1A1THRB | |
| Water SCHEMBL2745045 | 0.77 | HPGD (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL11591950 | 0.77 | HPGD (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504571-A | Right-embedded alcohol or fenchyl alcohol ester derivatives of 2-hydroxy nicotinic acid and pharmaceutical application thereof | 苏州缘聚医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-2632562-B1 | METHODS FOR CAPTURING VIRUS LIKE PARTICLES FROM PLANTS USING EXPANDED BED CHROMATOGRAPHY | PHILIP MORRIS PRODUCTS SA (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-20170282095-A1 | Process For Isolation of Plasma or Serum Proteins | THERAPURE BIOPHARMA INC. (CA) | 2017-10-05 | — | — | US | disclosed |
| EP-2832726-B1 | (2-HETEROARYLAMINO)SUCCINIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-9624260-B2 | Process for isolation of plasma or serum proteins | THERAPURE BIOPHARMA INC. (CA) | 2017-04-18 | — | — | US | disclosed |
| EP-3127916-A1 | ISOLATION OF PLASMA OR SERUM PROTEINS | Therapure Biopharma Inc. (CA) | 2017-02-08 | — | — | EP | disclosed |
| EP-2277912-B1 | Isolation of plasma proteins | THERAPURE BIOPHARMA INC (CA) | 2016-09-28 | — | — | EP | disclosed |
| US-9428545-B2 | Process for isolation of plasma or serum proteins | THERAPURE BIOPHARMA INC. (CA) | 2016-08-30 | — | — | US | disclosed |
| US-20160009757-A1 | PROCESS FOR ISOLATION OF PLASMA OR SERUM PROTEINS | THERAPURE BIOPHARMA INC. (CA) | 2016-01-14 | — | — | US | disclosed |
| US-9206168-B2 | (2-heteroarylamino) succinic acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-1401289-A1 | FRACTIONATION OF PROTEIN CONTAINING MIXTURES | UPFRONT CHROMATOGRAPHY A/S (DK) | 2004-03-31 | — | — | EP | disclosed |
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1386660-A1 | Isolation of proteins | UPFRONT CHROMATOGRAPHY A/S (DK) | 2004-02-04 | — | — | EP | disclosed |
| US-20030187227-A1 | Isolation of immunoglobulins | UPFRONT CHROMATOGRAPHY A/S | 2003-10-02 | — | — | US | disclosed |
| EP-1309565-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-05-14 | — | — | EP | disclosed |
| US-6498236-B1 | HYBRIDOMA CELL CULTURE SUPERNATANTS, ANIMAL PLASMA OR SERA, OR COLOSTRUM. THE METHOD INCLUDES THE USE OF A MINIMUM OF SALTS, SUCH AS LYOTROPIC SALTS, IN THE BINDING PROCESS AND PREFERABLY ALSO THE USE OF SMALL AMOUNTS OF ORGANIC SOLVENTS IN THE | UPFRONT CHROMATOGRAPHY A/S (DK) | 2002-12-24 | — | — | US | disclosed |
| WO-2002096215-A1 | FRACTIONATION OF PROTEIN CONTAINING MIXTURES | UPFRONT CHROMATOGRAPHY A/S (DK) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002012199-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-14 | — | — | WO | disclosed |
| US-4447422-A | Penicillins and compositions containing them | BEECHAM GROUP P.1.C. (GB) | 1984-05-08 | — | — | US | disclosed |
| EP-0067610-A1 | Penicillins, a process for their preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1982-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | MLN, MSH2, MRPL21 | GABRP 1337/4885GABRD 1284/4885GABRA1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.